Report from HUPO 2005 Munich



The Proteomics Standards Initiative session of the Human Proteome Organization (HUPO) 2005 congress was opened by the current chair, Rolf Apweiler of the European Molecular Biology Laboratory - European Bioinformatics Institute (EMBL-EBI), who summarized the achievements of the HUPO Proteomics Standards Initiative (HUPO-PSI) to date. The Molecular Interaction XML interchange standard is already widely used, and all of the major publicly available databases now make data available in this format [1].

Five of these databases -- BIND, DIP, IntAct, MINT, and MPact (MIPS) -- have formed the International Molecular Exchange consortium to jointly curate and exchange data, with data exchange commencing early in 2006. The mass spectrometry standard (PSI-MS mzData version 1.05) for the collection of raw peaklist data is being implemented by an increasing number of instrumentation and software manufacturers [2]. The Institute for Systems Biology in Seattle has also released a second standard that was developed for use in their analysis pipeline [3]. The two groups have agreed to work together to ensure that first the analysis standard (analysisXML) and later the two peaklist standards will be merged into a single entity to facilitate user adoption.

Henning Hermjakob of EMBL-EBI detailed the current status of the PSI-MI standard version 2.5, which has been frozen in preparation for release in September 2005. The standard has already been successfully implemented by one database, and others have committed to release within a few weeks of publication. It is planned that PSI-MI2.5 will be the supported standard from January 2006 and will be supported by both the current suite of tools and new applications such as PSIQUIC, a common query Web service API for all participating databases.

Hermjakob went on to describe work undertaken by Luisa Montecchi-Palazzi and John Garavelli of EMBL-EBI in developing an ontology of terms to describe protein modifications, both the natural and artifactual modifications observed by mass spectrometrists. This work will combine the modifications collected by three databases -- RESID, UniMod, and Delta Mass -- and the controlled vocabulary already developed for PSI-MI by Luisa Montecchi-Palazzi into a single resource for all proteomics studies.

The mass spectrometry group is now co-chaired by Randall Julian of Eli Lilly and Patrick Pedrioli of ISMB, Zurich. However, since neither was present at this pre-congress session, Chris Taylor of EMBL-EBI briefly updated the delegates with a list of manufacturers who have either already incorporated mzData v.1.05 into their procedures or are planning to do so on their next release. Merger with the ISB standard will have to be carefully planned, since a stable platform is vital to ensure vendor compliance.

One immediate benefit of the mzData standard is that the data generated by the HUPO tissue initiatives is now available in the PRIDE mzData-compatible database from where it can be accessed and downloaded for subsequent reanalysis. An initial meeting of the major current, and planned, proteomics mass spectrometry repositories was scheduled for immediately after the main congress to discuss data exchange. Taylor went on to describe the continuing efforts to describe a General Proteomics Standard. This group is now working with the FuGE (Functional Genomics Experiment) efforts to define a general standard in which to encode data, which will enable a systems biology approach to data analysis. Immediate future plans center on the development of standards for the description, storage, and exchange of gel electrophoresis data that are to developed over the next few months.

Rudi Aebersold of ISB, Swiss Federal Institute of Technology, Zurich, the chair-elect of the Bioinformatics committee, ended the session by praising the amazing progress made by the different groups and their already considerable contributions to the HUPO tissue initiatives. All the different strands are actively pushing these standards forward and ensuring their adoption by the scientific community and the associated instrumentation manufacturers.

All such efforts require support from the user community, and the HUPO-PSI is actively seeking input and advice from all quarters. Anyone wishing to become involved is invited to visit http://psidev.sf.net/ to participate in the discussion groups listed and to contribute to the further development of community standards for proteomics data.

Proteomics101: Data Profusion

The field of proteomics is increasingly broad and encompasses an expanding number of complex experimental techniques. Studies generate huge volumes of data that can include gel images, mass spectrometry spectra, and protein identifications, all of which poses enormous problems of analysis, interpretation, and storage for the original researcher.

The ability of researchers to vary the type of instrumentation and analytical methodology used from experiment to experiment only adds to the problem. It is not unusual for a proteomics group to possess more than one type of mass spectrometer and vary their choice of machine with the type of experiment. This can create problems for data comparison even within a single laboratory, since each instrument manufacturer typically provides its own proprietary program to analyze the output.

Publication of this data presents a further challenge. Currently, a typical paper describing a proteomics data set will consist of an experimental description, a summary data table, and an analysis and discussion of the data in that table. Additional supporting material is often supplied as a supplementary table, where it is not available in a format appropriate for reanalysis by a third party. Descriptions of the sample acquisition, preparation, and storage vary enormously, although these are crucial issues that have a direct impact on the final data set. Even an issue as fundamental as protein identity can often be confusing, with author-derived nomenclature failing to coincide with that used by the public-domain databases and accession numbers not being quoted.

The need to develop common data representation standards in the field of proteomics is apparent, with a requirement for a system that is both stable enough to provide a reliable platform for users, instrumentation manufacturers, and software developers to work from and flexible enough to keep pace with new developments in the field of both mass spectrometry and proteomics in general. To address this problem, HUPO [4] set its internal Bioinformatics committee the task of producing standards, initially to enable the transfer of information between laboratories participating in the HUPO tissue initiatives.

References

1 Hermjakob, H. et al. Nat Biotechnol 22, 177-83; 2004.

2 Orchard, S. et al. Proteomics 5, 3552-5; 2005.

3 Pedrioli, P.G. et al. Nat Biotechnol 22, 1459-66; 2004.

4 Kaiser, J. Science 296, 827; 2002.

Sandra Orchard, Henning Hermjakob, and Rolf Apweiler work for the EMBL-EBI. E-mail: orchard@ebi.ac.uk.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi whp 2
Managing the Modern Genomics Data Flood
Sponsored by SGI

Managing and storing the perfect storm of multi-disciplined data pouring from next generation sequencers and other omics instruments is a central challenge in life sciences. Discover in this paper how the SGI ArcFiniti storage solution, optimized for unstructured genomics and life sciences data can: 

  • Reduce costs, proactively protect data integrity, and deliver the high performance I/O required for genomics data processing and analysis.  
  • Effectively manage capacities from 156TB to 1.4PB as a disk based, integrated hardware and software platform 


sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .